Clostridium Difficile Infection Clinical Trial
Official title:
Physical Plant Design and Engineering Controls and the Prevention of Nosocomial Infections and Antibiotic Resistant Organism Colonization Events - A Proposal for a Prospective Controlled Trial
With the construction of a new medical teaching ward with features designed to reduce hospital-acquired infections, we hypothesized that the design of the new ward was the major factor that contributed to the improved outcomes and designed a prospective, controlled study to examine this hypothesis.
Recent studies have underscored the importance of optimizing design standards to maximize
patient and health care worker safety, including the prevention of hospital acquired
infections (HAI) in patients. Health care associated infections are a major contributor to
adverse events in healthcare, estimated to occur in 3-20% of all acute care admissions in
Canada. A review of the role of the physical environment and adverse events identified no
prospective randomized controlled trials of physical plant design and its impact on hospital
acquired infections. With the construction in 2004 of a unique $5-million, 36-bed medical
teaching unit at Foothills Medical Centre (FMC) with a prototypical design with features to
reduce HAI and an overarching mandate to test new concepts in health care delivery, the
opportunity exists to rigorously study the impact of design, construction and engineering
controls (DCECs) on specific hospital acquired infections and antibiotic resistant organism
(ARO) colonization. In the first year of operation the incidence density of hospital acquired
infections and/or colonization with marker organisms has declined by almost 70%. Given that
there were no changes in the types of patients, medical, nursing or housekeeping staff, we
hypothesized that the design of the new ward was the major factor which contributed to the
improved outcomes. Given the pre-post study design we are uncertain as to which factor is
most important in reducing HAI /colonization rates.
We therefore propose to conduct a prospective, controlled investigator blinded trial of the
impact of DCECs on specific HAIs and ARO colonization. We propose to allocate general medical
patients, with an allocation scheme that incorporates randomness, to one of 2 types of
medical wards at the FMC, either "historic design" wards (ie control wards in the
non-renovated portions of FMC or Unit 36 (the experimental new design ward). The medical
wards are very similar with respect to the patient mix, acuity of care, medical staff,
nursing staff and skill mix, educational levels, housekeeping and levels of knowledge about
infection control practices but differ in design. Variables which may otherwise have
confounded the outcome of hospital acquired infections/colonizations may be controlled
allowing the effect of the differences in design, construction and engineering controls to be
studied. The older design wards have predominantly 4-bed and some 2-bed rooms with shared
bathrooms, less space and fewer handwashing sinks/patient. The study will require 9750
patient days of observation in the "historic design"wards and 19,500 patient days of
observation in Unit 36 to ensure 80% statistical power to detect a 60% difference in the
rates of incident cases of selected HAIs and ARO colonizations (the primary outcome measure)
with an α level of 0.05 assuming that incident cases in each unit follow Poisson distribution
based on well established historic trends on these units.
In addition we propose to add a nested mixed methods social science study within the
construct of the prospective study to understand the fit between the health care workers and
the physical environment. In recognition that the proposed intervention may be defined as a
"complex intervention" with HAIs affected by many factors related to physical plant design,
organizational factors, and health care worker practices, it was considered prudent to
measure and describe worker and organizational factors on the medical inpatient care units
included in the proposed intervention.
Our proposed study is being done with the collaboration and support of both the Operations
and Planning & Capital Development portfolios of the Calgary Health Region. The Region is in
the throes of a major expansion with over $1 billion of new capital health care developments
and the addition of over 700 new beds by 2010. The finding of favorable outcomes on the
medical ward with its special design, construction and engineered controls in a well designed
prospective study of this nature would be the first of its kind and has the potential to
change the fundamental design of new medical wards in the Calgary Health Region and in other
jurisdictions within Canada.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02214771 -
Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients
|
N/A | |
Withdrawn |
NCT01552668 -
Fidaxomicin to Prevent Clostridium Difficile Colonization
|
Phase 4 | |
Recruiting |
NCT03325855 -
Fecal Microbiota Transplant National Registry
|
||
Not yet recruiting |
NCT03586206 -
Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
|
||
Suspended |
NCT03350711 -
A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program
|
||
Withdrawn |
NCT03643887 -
Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients
|
Phase 2 | |
Terminated |
NCT04000555 -
Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)
|
Phase 4 | |
Terminated |
NCT03065374 -
Treatment for Clostridium-difficile Infection With IMM529
|
Phase 1/Phase 2 | |
Completed |
NCT03710694 -
Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI)
|
N/A | |
Completed |
NCT02865616 -
MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)
|
Phase 1 | |
Recruiting |
NCT04940468 -
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
|
N/A | |
Completed |
NCT02589847 -
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
|
Phase 2 | |
Not yet recruiting |
NCT01942447 -
Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis
|
N/A | |
Active, not recruiting |
NCT02086916 -
Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection
|
N/A | |
Completed |
NCT01230957 -
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
|
Phase 2 | |
Completed |
NCT01241552 -
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
|
Phase 3 | |
Not yet recruiting |
NCT04567134 -
Clostridioides Difficile Infection - a Prospective Nationwide Epidemiologic Study in Korea
|
||
Completed |
NCT04075422 -
Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.
|
||
Recruiting |
NCT03712722 -
Fecal Microbiota Transplantation (FMT) for Clostridium Difficile
|
||
Recruiting |
NCT05192148 -
Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile
|
N/A |